Want to see SPRB full AI Analyst Report?
SPRB Stock Chart & Stats
$70.30
--
Market closed
$70.30
--
Day’s Range― - ―
52-Week Range$5.42 - $240.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)988.68K
Market Cap
$142.40M
Enterprise Value$19.94M
Total Cash (Recent Filing)$54.08M
Total Debt (Recent Filing)$7.12M
Price to Earnings (P/E)―
Beta-10.08
Next Earnings
Aug 17, 2026EPS Estimate
-6.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-37.60
Shares Outstanding2,752,278
10 Day Avg. Volume2,922,716
30 Day Avg. Volume988,676
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.57
Price to Sales (P/S)0.00
P/FCF Ratio-2.00
Enterprise Value/Market Cap0.14
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.55
Forecast
1Y Price Target
$149.71Price Target Upside112.96% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-23.83
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageVery low reported leverage and minimal interest burden improve solvency resilience for a clinical-stage biotech. This reduces near-term bankruptcy risk and gives management flexibility to fund development through equity or modest debt, supporting program continuity over the next 2–6 months.
Recent Capital RaiseA sizable $69M equity raise meaningfully extends runway for clinical programs and reduces immediate dilution pressure from reactive financings. Improved liquidity supports planned late‑stage activities and regulatory interactions, lowering execution risk for near‑term development milestones.
Strategic Pipeline Focus & Regulatory ProgressRefocusing resources on TA‑ERT with favorable Type B feedback and disease‑modifying signals strengthens the company’s strategic clarity and regulatory pathway. Hiring senior commercial and regulatory leaders improves launch preparedness and governance for a potential rare‑disease approval.
Bears Say
No Recent RevenueThe absence of product revenue means Spruce cannot self-fund operations and must convert R&D programs into approvals to generate sustainable income. Persistent operating losses erode equity and magnify dependency on external capital to progress trials and regulatory filings over the medium term.
Consistent Cash BurnMaterial negative operating and free cash flow require ongoing financing to support development. Even with recent raises, continued cash burn leaves the company exposed to capital‑market access risk; any delay in milestone or approval timing could necessitate dilutive raises that pressure long‑term shareholder value.
Loss Of Partner EconomicsTermination of the Kaken deal removes non‑dilutive funding and foreseeable milestone/royalty streams, increasing reliance on in‑house development and financing. This narrows diversification of commercial pathways and heightens execution risk, especially in Japan where partner access had supported program reach.
Spruce Biosciences News
SPRB FAQ
What was Spruce Biosciences’s price range in the past 12 months?
Spruce Biosciences lowest stock price was $5.42 and its highest was $240.00 in the past 12 months.
What is Spruce Biosciences’s market cap?
Spruce Biosciences’s market cap is $142.40M.
When is Spruce Biosciences’s upcoming earnings report date?
Spruce Biosciences’s upcoming earnings report date is Aug 17, 2026 which is in 37 days.
How were Spruce Biosciences’s earnings last quarter?
Spruce Biosciences released its earnings results on May 13, 2026. The company reported -$8.94 earnings per share for the quarter, missing the consensus estimate of -$7.934 by -$1.006.
Is Spruce Biosciences overvalued?
According to Wall Street analysts Spruce Biosciences’s price is currently Undervalued.
Does Spruce Biosciences pay dividends?
Spruce Biosciences does not currently pay dividends.
What is Spruce Biosciences’s EPS estimate?
Spruce Biosciences’s EPS estimate is -6.04.
How many shares outstanding does Spruce Biosciences have?
Spruce Biosciences has 2,752,278 shares outstanding.
What happened to Spruce Biosciences’s price movement after its last earnings report?
Spruce Biosciences reported an EPS of -$8.94 in its last earnings report, missing expectations of -$7.934. Following the earnings report the stock price went up 1.562%.
Which hedge fund is a major shareholder of Spruce Biosciences?
Currently, no hedge funds are holding shares in SPRB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Spruce Biosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$149.71 (112.96% Upside)
$149.71 (112.96% Upside)
Hedge Fund Trend
Decreased
By 16.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▲ 0.8%
Last 30 Days ▼ 0.5%
Last 30 Days ▼ 0.5%
Technicals
SMA
Positive
20 days / 200 days
Momentum
312.60%
12-Months-Change
Fundamentals
Return on Equity
-155.40%
Trailing 12-Months
Asset Growth
77.47%
Trailing 12-Months
Company Description
Spruce Biosciences
Spruce Biosciences, Inc., founded in 2014 and situated in Daly City, California, operates as a biopharmaceutical enterprise. Its primary objective is to advance and bring to market innovative treatments, particularly for uncommon endocrine conditions. A central component of its therapeutic pipeline is tildacerfont, a non-steroidal drug candidate. This compound is currently undergoing Phase 2b clinical assessments in adult patients with congenital adrenal hyperplasia (CAH), with the aim of optimizing disease management and lessening dependence on steroid medications by examining reductions in glucocorticoid levels and their clinical consequences. Tildacerfont is also progressing through Phase 2 trials for pediatric classic CAH, as well as investigating its efficacy in women suffering from polycystic ovary syndrome (PCOS). Additionally, Spruce Biosciences maintains a collaborative licensing agreement with Eli Lilly and Company to jointly explore, formulate, and commercialize various pharmaceutical substances.
SPRB Stock 12 Month Forecast
Average Price Target
$149.71
▲(112.96% Upside)
Technical Analysis
Ownership Overview
66.21% Insiders
1.04% Mutual Funds
12.90% Other Institutional Investors
12.52% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---